Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. T. van Meerten

Publications

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

High frequency of hyperglycaemia observed during CAR T-cell treatment

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

MO-0960 Evaluating semi-automated 18F-FDG PET segmentation methods to predict Large B-cell lymphoma outcomes

Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities

Reduction of Metabolic Active Tumor Volume Prior to CAR T-Cell Therapy Improves Survival Outcomes in Patients with Large B-Cell Lymphoma

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study

Read more

Press/media

Groningse CAR-T-celtherapie krijgt KWF-subsidie

Hoe een Gronings ziekenhuis het opneemt tegen big pharma

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Dit was 2021: Genezen

UMCG gaat zelf medicijn tegen lymfeklierkanker maken

Podcast De Genezers over CAR T-celtherapie

Gronings ziekenhuis gaat prijzig kankermedicijn zelf maken met miljoenensubsidie

€ 30 miljoen subsidie voor UMCG-onderzoek naar veelbelovende kankerbehandeling

Wanneer milieuwetgeving de strijd tegen kanker hindert

Doorbraak in behandeling lymfeklierkanker

Read more